In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.
A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...
AGC Biologics will help the company develop and manufacture RDP-101 in line with FDA standards and for the commercial market.
The payment was triggered because Kura dosed the first AML patient in a Phase III trial of the menin inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback